

Adrian Towse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11983373/publications.pdf>

Version: 2024-02-01

94
papers

3,119
citations

159585

30
h-index

168389

53
g-index

99
all docs

99
docs citations

99
times ranked

3056
citing authors

#	ARTICLE	IF	CITATIONS
1	Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of "Failed" R&D Efforts. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, 1-17.	0.5	6
2	Considering Severity in Health Technology Assessment: Can We Do Better?. <i>Value in Health</i> , 2022, 25, 1399-1403.	0.3	12
3	Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 651-667.	2.1	14
4	Not cost-effective at zero price: valuing and paying for combination therapies in cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 331-333.	1.4	7
5	Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.. <i>Medical Decision Making</i> , 2021, 41, 255-257.	2.4	2
6	Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 13.	1.5	8
7	Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop. <i>BMC Health Services Research</i> , 2021, 21, 412.	2.2	11
8	How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?. <i>Value in Health</i> , 2021, 24, 625-631.	0.3	9
9	Cornerstones of "fair" drug coverage: appropriate cost-sharing and utilization management policies for pharmaceuticals. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 537-547.	1.4	5
10	Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. <i>Value in Health</i> , 2021, 24, 1628-1633.	0.3	11
11	Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. <i>BMJ Global Health</i> , 2020, 5, e002061.	4.7	2
12	Establishing a reasonable price for an orphan drug. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 31.	1.5	47
13	Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 400-406.	0.9	10
14	Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1045-1054.	1.4	2
15	A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1082-1087.	0.9	15
16	Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?. <i>Value in Health</i> , 2019, 22, 677-683.	0.3	23
17	Is rate of return pricing a useful approach when value-based pricing is not appropriate?. <i>European Journal of Health Economics</i> , 2019, 20, 945-948.	2.8	14
18	Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. <i>European Journal of Health Economics</i> , 2019, 20, 427-438.	2.8	85

#	ARTICLE	IF	CITATIONS
19	Affordability of New Technologies: The Next Frontier. Value in Health, 2018, 21, 249-251.	0.3	19
20	Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]. Value in Health, 2018, 21, 140-145.	0.3	48
21	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 2018, 21, 161-165.	0.3	113
22	Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]. Value in Health, 2018, 21, 146-154.	0.3	59
23	Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in Health, 2018, 21, 276-279.	0.3	25
24	Gene therapy: evidence, value and affordability in the US health care system. Journal of Comparative Effectiveness Research, 2018, 7, 15-28.	1.4	84
25	Real-world evidence for coverage decisions: opportunities and challenges. Journal of Comparative Effectiveness Research, 2018, 7, 1133-1143.	1.4	59
26	A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions. Journal of Comparative Effectiveness Research, 2018, 7, 1145-1152.	1.4	12
27	Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health, 2017, 20, 213-216.	0.3	79
28	Indication-specific pricing of pharmaceuticals in the US healthcare system. Journal of Comparative Effectiveness Research, 2017, 6, 397-404.	1.4	33
29	Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy, 2017, 121, 1025-1030.	3.0	63
30	ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA. International Journal of Technology Assessment in Health Care, 2017, 33, 315-322.	0.5	3
31	Value assessment in precision cancer medicine. Journal of Cancer Policy, 2017, 11, 48-53.	1.4	12
32	Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. Journal of Personalized Medicine, 2017, 7, 10.	2.5	43
33	Health Economic Perspectives of Genomics. , 2016, , 83-117.		0
34	International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology, 2016, 34, 2936-2937.	1.6	12
35	Mapping Priority Setting in Health in 17 Countries Across Asia, Latin America, and sub-Saharan Africa. Health Systems and Reform, 2016, 2, 71-83.	1.2	25
36	Biosimilars: How Can Payers Get Long-Term Savings?. Pharmacoeconomics, 2016, 34, 609-616.	3.3	67

#	ARTICLE	IF	CITATIONS
37	Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria. <i>Oxford Review of Economic Policy</i> , 2016, 32, 64-87.	1.9	3
38	IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 449-456.	0.5	4
39	UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 363-370.	0.5	6
40	RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 371-379.	0.5	2
41	PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 90-98.	0.5	16
42	Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 385-400.	1.4	8
43	European Union Pharmaceutical Markets: A Case for Differential Pricing?. <i>International Journal of the Economics of Business</i> , 2015, 22, 263-275.	1.7	29
44	The future of comparative effectiveness and relative efficacy of drugs: an international perspective. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 419-427.	1.4	8
45	Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 401-418.	1.4	5
46	Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context. <i>Health Economics (United Kingdom)</i> , 2015, 24, 294-301.	1.7	76
47	Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. <i>American Journal of Managed Care</i> , 2015, 21, 632-40.	1.1	41
48	Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 268-277.	1.9	4
49	Orphan drugs policies: a suitable case for treatment. <i>European Journal of Health Economics</i> , 2014, 15, 335-340.	2.8	64
50	Reforming the Cancer Drug Fund. <i>BMJ, The</i> , 2014, 349, g7276-g7276.	6.0	7
51	Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. <i>Value in Health</i> , 2013, 16, 703-719.	0.3	237
52	Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine. <i>Value in Health</i> , 2013, 16, S39-S43.	0.3	46
53	Operationalizing Value-Based Pricing of Medicines. <i>Pharmacoeconomics</i> , 2013, 31, 1-10.	3.3	84
54	A REVIEW OF HEALTH TECHNOLOGY APPRAISALS: CASE STUDIES IN ONCOLOGY. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 101-109.	0.5	14

#	ARTICLE	IF	CITATIONS
55	APPROACHES TO IDENTIFYING, MEASURING, AND AGGREGATING ELEMENTS OF VALUE. International Journal of Technology Assessment in Health Care, 2013, 29, 360-364.	0.5	21
56	Can and should value-based pricing be applied to molecular diagnostics?. Personalized Medicine, 2013, 10, 61-72.	1.5	30
57	Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned. Journal of Personalized Medicine, 2013, 3, 288-305.	2.5	22
58	Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report. Value in Health, 2012, 15, 217-230.	0.3	151
59	Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health, 2012, 15, 1162-1171.	0.3	119
60	Drugs and Vaccines for Developing Countries. , 2012, , .		8
61	Measuring Value: Pharmacoeconomics Theory and Practice. , 2012, , .		1
62	The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?. SSRN Electronic Journal, 2012, , .	0.4	3
63	Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?. European Journal of Health Economics, 2012, 13, 1-5.	2.8	42
64	El uso del pago por resultados para los fármacos: ¿Puede mejorar los incentivos para la innovación?. , 2012, , 79-91.		0
65	Using QALYs in Cancer. Pharmacoeconomics, 2011, 29, 673-685.	3.3	74
66	Incentives for R&D for New Antimicrobial Drugs. International Journal of the Economics of Business, 2011, 18, 331-350.	1.7	13
67	Setting Cost-Effectiveness Thresholds As A Means To Achieve Appropriate Drug Prices In Rich And Poor Countries. Health Affairs, 2011, 30, 1529-1538.	5.2	25
68	The use of pay-for-performance for drugs: Can it improve incentives for innovation?. , 2011, , 69-80.		1
69	Net Clinical Benefit: The Art and Science of Jointly Estimating Benefits and Risks of Medical Treatment. Value in Health, 2010, 13, S30-S32.	0.3	10
70	Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?. British Journal of Clinical Pharmacology, 2010, 70, 360-366.	2.4	48
71	Can't Get No Satisfaction? Will Pay for Performance Help?. Pharmacoeconomics, 2010, 28, 93-102.	3.3	102
72	Should NICE's threshold range for cost per QALY be raised? Yes. BMJ: British Medical Journal, 2009, 338, b181-b181.	2.3	78

#	ARTICLE	IF	CITATIONS
73	Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis. Health Affairs, 2007, 26, 684-695.	5.2	75
74	If it ain't broke, don't price fix it: the OFT and the PPRS. Health Economics (United Kingdom), 2007, 16, 653-665.	1.7	24
75	Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bulletin of the World Health Organization, 2005, 83, 301-7.	3.3	14
76	Learning from Thailand's health reforms. BMJ: British Medical Journal, 2004, 328, 103-105.	2.3	88
77	Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics, 2003, 3, 183-205.	1.2	194
78	The Drug Budget Silo Mentality in Europe: An Overview. Value in Health, 2003, 6, S1-S9.	0.3	43
79	The Efficient Use Of Pharmaceuticals: Does Europe Have Any Lessons For A Medicare Drug Benefit?. Health Affairs, 2003, 22, 42-45.	5.2	20
80	National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working?. Pharmacoeconomics, 2002, 20, 95-105.	3.3	34
81	The Economics of Gene Therapy and of Pharmacogenetics. Value in Health, 2002, 5, 5-13.	0.3	79
82	The Genomic Revolution: Is the Real Risk Under-Investment Rather than Bankrupt Health Care Systems?. Journal of Health Services Research and Policy, 2000, 5, 253-255.	1.7	17
83	Joint Disease Management Ventures in the UK. Journal of Integrated Care, 1999, 3, 71-78.	0.3	0
84	Medical negligence and the NHS: an economic analysis. Health Economics (United Kingdom), 1999, 8, 93-101.	1.7	25
85	The Pros and Cons of a Single Euro-Price For Drugs. Pharmacoeconomics, 1998, 13, 271-276.	3.3	10
86	The Pros and Cons of a Single Euro-Price for Drugs and The Economics of Parallel Trade. Pharmacoeconomics, 1998, 14, 135-137.	3.3	1
87	The UK Pharmaceutical Market. Pharmacoeconomics, 1996, 10, 14-25.	3.3	11
88	The Pricing and Reimbursement of Pharmaceuticals. Pharmacoeconomics, 1994, 6, 36-38.	3.3	4
89	New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. SSRN Electronic Journal, 0, , .	0.4	13
90	Incentives for R&D for New Antimicrobial Drugs. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?. SSRN Electronic Journal, 0, , .	0.4	5
92	Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches. SSRN Electronic Journal, 0, , .	0.4	2
93	Comparative and Relative Effectiveness: A Challenge for Health Systems, Regulators, or Pharmaceutical Companies?. SSRN Electronic Journal, 0, , .	0.4	0
94	Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases. Applied Economics Letters, 0, , 1-5.	1.8	0